The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Jiangsu Hengrui Medicine
Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study.
 
Li Chen
No Relationships to Disclose
 
Shao Zhimin
No Relationships to Disclose
 
Zhonghua Wang
No Relationships to Disclose
 
Wentao Yang
No Relationships to Disclose
 
Yizhou Jiang
No Relationships to Disclose
 
Jianjun Zou
No Relationships to Disclose
 
Jiong Wu
No Relationships to Disclose
 
Genhong Di
No Relationships to Disclose
 
Guangyu Liu
No Relationships to Disclose
 
Keda Yu
No Relationships to Disclose
 
Lei Fan
No Relationships to Disclose
 
Junjie Li
No Relationships to Disclose
 
Yifeng Hou
No Relationships to Disclose
 
Zhen Hu
No Relationships to Disclose
 
Canming Chen
No Relationships to Disclose
 
Xiaoyan Huang
No Relationships to Disclose
 
Ayong Cao
No Relationships to Disclose
 
Xin Hu
No Relationships to Disclose
 
Songyang Wu
No Relationships to Disclose
 
Shen Zhao
No Relationships to Disclose